Detailed Narrative
Strong Financial Performance and Margin Expansion in FY26
Amanta Healthcare reported a robust financial performance for FY26, with revenue reaching INR 288 crores, marking a 5% year-on-year growth. Profitability saw significant improvement, with PAT growing over 42% year-on-year to INR 15 crores. The company maintained a stable EBITDA margin of 22% for the full year, and PAT margin expanded by 100 basis points to 5%, reflecting effective cost control and operating leverage.
Strategic Capacity Expansion and Operational Readiness
The company is expanding its SteriPort capacity from 6.6 crore bottles to 12 crore bottles per year, with the new line expected to be operational by June 20, 2026. This expansion is crucial for capturing the growing IV fluid market, particularly the two-port system segment. Additionally, a 10.8 MW captive solar power project is nearing commissioning (expected by May 30, 2026), which is projected to save INR 75 lakh per month from Q1 FY27, enhancing energy efficiency and reducing operational costs.
Significant Balance Sheet Deleveraging
Amanta Healthcare has made substantial progress in strengthening its balance sheet, reducing its debt-to-equity ratio from 3x to nearly 1x over the last three years. The company has replaced expensive debt with cheaper alternatives, resulting in approximately 90% of its borrowing now being in single-digit interest rates. The total debt as of March '26 was INR 234 crores, which has further reduced to INR 204 crores by the call date due to early April repayments.
Product Portfolio and Market Traction
The SteriPort platform continues to be a key growth driver, contributing nearly 42% of the revenue. Built on advanced ISBM technology, SteriPort offers superior sterilization and lower contamination risk. The company is also strengthening its Small Volume Parenterals (SVP) portfolio, focusing on high-value segments like inhalation solutions and preservative-free ophthalmics, which contribute nearly 20% of SVP revenue.
Raw Material Price Management and Pricing Strategy
The company acknowledged a significant increase of 60-70% in polymer raw material prices. However, management stated that they have revised their product prices, including an approximate INR 2 per bottle increase for SteriPort, and have not encountered resistance from the market. This proactive pricing strategy aims to maintain gross margins and ensure neutrality against rising input costs.
Market Outlook and Growth Drivers
The Indian IV fluid consumption market is growing at 8-10% year-on-year, with an incremental demand of 12-15 crore bottles annually. The two-port system segment is growing even faster at 12-13% due to conversion from conventional packs. Amanta aims for a 20-25% market share in the two-port system by 2030, focusing on specialized and differentiated products rather than aggressive generic market share.
Operational Efficiencies and Future Growth Priorities
Beyond the solar project, the company is implementing various initiatives to improve operational efficiencies. Key priorities for FY27 include enhancing regulatory approvals, developing a product pipeline (currently 20 products in pipeline), expanding export opportunities in both advanced and semi-regulated markets, and maintaining financial prudence while executing growth capex. The working capital cycle is targeted to improve from 120-125 days to 110 days in the near future.